SONY-DADC-BIOSCIENCES
MyCartis , the provider of fully integrated and broadly applicable molecular diagnostics and immunodiagnostics solutions, and Sony DADC BioSciences today announced the cooperation in the production of a microfluidic assay cartridge for MyCartis’ EvalutionTM digital multiplex analysis platform to support a range of applications in the clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160229005056/en/
Sony DADC BioSciences, a leading supplier of smart polymer parts for the biomedical industry, is using their ISO 13485-certified facility in Salzburg, Austria for manufacturing. The customized foil bonded cartridge is manufactured as a monolithic molded microtiter size plate that has optical transparency and combines macrostructures, high precision microstructures and filter structures for achieving the ultra-sensitivity of the EvalutionTM System.
“We are very pleased to be working with Sony DADC BioSciences as our development and manufacturing partner for the EvalutionTM cartridge. The collaboration between the two companies brings together a broad range of knowledge and experience, which are important for the success of innovative new technologies such as the EvalutionTM System,” said Joris Schuurmans, CEO of MyCartis.
The highly integrated assay cartridge contains reaction and detection chambers to ensure short time to result and minimal processing steps. Next to the ability to run 1 to 16 samples at the same time the EvalutionTM System further delivers superior data quality and rapid results.
“We are fascinated about MyCartis’ flexible EvalutionTM platform and enjoy our mutual team spirit. From a manufacturing perspective, the project enhances our capabilities in both injection molding and bonding of microfluidic consumables in micro titer plate format – the de facto industry standard,” said Werner Balika, Engineering Manager at Sony DADC BioSciences GmbH.
About MyCartis
MyCartis' innovative research and diagnostic system, called EvalutionTM , features the measurement and detection of molecular components of different nature (proteins, nucleic acids…), indicative of a specific pathological state in a multiplex format. The new semi-automated system is highly user-friendly thanks to its integrated workflow and provides rapid and robust results thanks to improved kinetics in the microfluidic channels. In addition, MyCartis develops ready-to-use multiplex assays with major clinical and compelling health economic values, through its own development efforts as well as through strategic partnerships. Oncology, neurology, cardiology and immunology are MyCartis' primary focus.
For more information please visit http://www.mycartis.net/
About Sony DADC BioSciences GmbH
Building on Sony DADC’s experience in high-precision optical disc manufacturing, Sony DADC BioSciences partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts.
For more information please visit http://biosciences.sonydadc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005056/en/
Contact:
MyCartis NV
François Topin
+32 9 241 11 60
ftopin@mycartis.net
or
Sony
DADC BioSciences GmbH
Ricarda Pichler
+43 6246 880 8142
ricarda.pichler@sonydadc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom